Ticker brief
KRRO
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
4
crowd 14d
+0.10
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-06 · now +0.07 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 2 | +0.10 |
| @CrweWorld | C | · | 1 | +0.20 |
| @PrismMarketView | C | · | 1 | +0.10 |
| @PrismDM | A | -2.76 | 1 | +0.10 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-06 | @OzmosiHealth | +0.00 | Korro Bio schedules Phase 2 KRRO-121 results for the second half of 2027. | · | tweet ↗ |
| 2026-10-06 | @PrismDM | +0.10 | Korro Bio dosed the first healthy-volunteer cohort in its Phase 1/2 RNA-editing trial. | · | tweet ↗ |
| 2026-10-06 | @PrismMarketView | +0.10 | KRRO dosed the first cohort in a Phase 1/2 RNA-editing trial. | · | tweet ↗ |
| 2026-10-05 | @CrweWorld | +0.20 | Korro reports the first cohort dosed in a Phase 1/2 clinical trial. | · | tweet ↗ |
| 2026-10-05 | @OzmosiHealth | +0.20 | Korro announced dosing of the first cohort in its Phase 1/2 ANCHOR trial. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.